Every Whitepill guide
6 guides across 2 topics. Each prints the date its figures were read at their primary sources and the date it will be read again.
Compound checks
All CompoundsBPC-157: status, trials and harms
FDA lists it as nominated and withdrawn, PubMed has no trial-tagged papers, and neither an advisory vote nor a new HHS draft policy is an approval.
Read the receipttrial-tagged papers on PubMed (semaglutide has 344, for scale only)
MK-677 (ibutamoren): status, trials and harms
The deepest trial record of any unapproved compound in the table, and FDA still lists it in Category 2 for a heart-failure risk.
How FDA's peptide categories work
Category 1, 2, 3 and "withdrawn", which peptides sit where, and why a vote or a label is not a ruling.
HHS peptide enforcement notice: what it says
A draft, non-binding HHS policy on compounding certain peptides: what it is not, who it covers, and when comments close.
The evidence ladder
All The ladderThe evidence ladder: trial depth by topic
Training, creatine, sleep, sunscreen, skin and hair care and BPC-157, counted from public registries.
Read the receipt3,954 vs 0papers tagged as trials, a depth count and not effect or quality: resistance training against BPC-157
Steroid era vs peptide era: the harm data
Published cohorts link non-medical steroid use with higher mortality and heart disease; most peptides have almost no harm data. Missing data is not safety.